0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Allied
Its shares trade under the ticker ALID. It has been listed since 4 December 2018. In the fiscal year to 31 August 2024, it reported revenue of $96,180 and a net loss of $4.0m. At that date it held total assets of $2.1m and shareholders' equity of −$7.5m.
Allied Corp. engages in the research, creation, and production of cannabinoid health solutions. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2018-12-04. The firm is focused on the development of medicinal cannabis and psilocybin products for patients with conditions potentially suitable for treatment there with. Such conditions include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder (PTSD), Parkinson’s disease, Tourette syndrome, irritable bowel syndrome (IBS) and spasticity associated with multiple sclerosis (MS) and spinal cord injury (SCI)1. Its wholly owned subsidiaries include AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd., and Allied Colombia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 4 Dec 2018
- Website
- allied.health ↗
Leadership
Pay as last reported
- Mr. Calum HughesChairman of the Board, since 2019$109,767
- Mr. Paul BullockChief Operating Officer, Interim Chief Financial Officer and Director, since 2020$92,627
- Mr. Jim SmeedingVice President of Pharmaceuticals, Director, since 2020$60,000
- Mr. Michael MosesChief Business Development Officer$150,029
- Mr. Abdul Musoke NnyenjeDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Allied Corp focuses on cannabinoid health solutions for chronic pain and PTSD treatment in Canada.
- Allied Corp's subsidiaries include AM Biosciences and Allied US Products LLC for global market expansion.
- Allied Corp's IPO on 12-04-2018 provided capital for research and development in pharmaceuticals.
Weaknesses
- Allied Corp's focus on cannabinoid products faces regulatory challenges in the United States.
- Allied Corp's operations in Colombia require navigating complex international regulations.
- Allied Corp's reliance on psilocybin products may face limited market acceptance.
Opportunities
- Allied Corp can expand its cannabinoid solutions into the U.S. market with regulatory changes.
- Allied Corp can leverage its subsidiaries to enter the European pharmaceutical market.
- Allied Corp can develop new products for irritable bowel syndrome (IBS) and spasticity treatment.
Threats
- Allied Corp faces competition from established pharmaceutical companies in the Health Care sector.
- Allied Corp's psilocybin products may encounter legal restrictions in multiple countries.
- Allied Corp's operations in Colombia could be affected by political instability in South America.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.